Clinical Trials Logo

IgG Deficiency clinical trials

View clinical trials related to IgG Deficiency.

Filter by:
  • None
  • Page 1

NCT ID: NCT06355323 Recruiting - Clinical trials for Primary Immunodeficiency

Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France

PREDDICHA
Start date: November 28, 2022
Phase: N/A
Study type: Interventional

Primary humoral immunodeficiency (PHID), such as common variable immunodefiency, are the most common symptomatic primary immunodeficiency in adults, in France. Patients are more prone to infections (particularly bacterial upper and lower respiratory tract infections), auto-immunity and atopic manifestations. Morbidity and mortality in PHID are mainly linked to the presence of bronchiectasis, which can lead to infections and to chronic respiratory failure. However, bronchiectasis in these patients can be asymptomatic for a long time. There is no known predictive factors to identify patients more susceptible to develop bronchiectasis and notably, there was no link between the number of previous infectious episodes and bronchiectasis. A marked IgM deficiency and switched memory B cell deficiency might be associated with bronchiectasis. Thoracic CT-scan is recommended at PHID diagnosis but there is no guideline for follow-up, thus leading to bronchiectasis being under-diagnosis or leading to delayed diagnosis

NCT ID: NCT05621876 Not yet recruiting - Clinical trials for Primary Immunodeficiency Diseases

Evaluation of an IgG Deficiency Rapid Screening Test: A Performance Study With Primary Immunodeficiency (PID) Patients in Tunisia

Start date: May 15, 2024
Phase:
Study type: Observational

To evaluate the usability and utility of the device, % agreement between the PID-RDT and the referent assay (serum/plasma), and % agreement between capillary blood and venous blood samples using the PID-RDT within confirmed PID patients prior to receipt of their monthly IV-Ig treatment.

NCT ID: NCT01992328 Active, not recruiting - Asthma Clinical Trials

IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency

IVIG
Start date: December 2013
Phase: Phase 3
Study type: Interventional

Immunoglobulin G deficiency subtypes in patients with asthma six months once a month intravenous immunoglobulin (400mg/kg/4weeks) infection in treatment-related effect on reducing the frequency of asthma exacerbations appreciate.

NCT ID: NCT01847781 Completed - IgG Deficiency Clinical Trials

PNEUMOCELL - Conjugated Pneumococcal Vaccination in Patients With Immunoglobulin G-deficiency

PNEUMOCELL
Start date: May 2013
Phase: Phase 2
Study type: Interventional

The aim is to study the immune response to conjugated pneumococcal vaccination (Prevenar13) in Immunoglobulin G-deficient patients and healthy controls. Our hypothesis is that the antibody response will be impaired in patients as compared with controls. In contrast, we postulate that the cellular immune response will be intact.

NCT ID: NCT00522821 Completed - Infections Clinical Trials

Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response

Subklasse
Start date: November 2007
Phase: Phase 4
Study type: Interventional

There is no consensus on the treatment of patients with recurrent infections and isolated immunoglobulin G (IgG)-subclass deficiency and/or selective antipolysaccharide antibody deficiency. Therefore, the Dutch Inter University Working Party will start a study in which the treatment with antibiotics is compared with intravenous immunoglobulin therapy with respect to clinical outcome measures in both children and adults with this disorder.

NCT ID: NCT00417573 Completed - Infections Clinical Trials

Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections

Start date: December 2004
Phase: Phase 2
Study type: Interventional

- This is the first study, that we are aware of, that will evaluate the efficacy of IgIV in patients with IgG subclass deficiency. - Will provide data for further collaboration in extending study to involve other immunological centers in the United States to study patients with similar disease.

NCT ID: NCT00322556 Completed - Clinical trials for Common Variable Immunodeficiency

Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

Start date: November 2005
Phase: Phase 3
Study type: Interventional

The objectives of this trial are the assessment of safety and efficacy of IgPro10 in patients with PID, and the assessment of tolerability of high infusion rates. To demonstrate safety, the number of infusions temporally associated with AEs, the rate, severity and relationship of all AEs and the vital sign changes during each infusion will be evaluated.

NCT ID: NCT00168025 Completed - Clinical trials for Common Variable Immunodeficiency

Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

Start date: September 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the effect of IgPro10 on the prevention of serious bacterial infections in patients with primary immunodeficiency. As secondary endpoints the rate of overall infections, the tolerability and safety of IgPro10 are studied. A part of the patients are participating in a pharmacokinetic substudy.

NCT ID: NCT00168012 Completed - Clinical trials for Common Variable Immunodeficiency

Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

Start date: September 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the effect of IVIG-F10 on the prevention of serious bacterial infections in patients with primary immunodeficiency. As secondary endpoints the rate of overall infections, the tolerability and safety of IVIG-F10 are studied.